Skip to main content
. 2015 Sep 22;2015(9):CD001191. doi: 10.1002/14651858.CD001191.pub4

Comparison 5. Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 ADAS‐J Cog (change from baseline at 24 weeks) ITT 1 531 Mean Difference (IV, Fixed, 95% CI) ‐0.8 [‐1.62, 0.02]
2 MMSE (change from baseline at 24 weeks) ITT 1 487 Mean Difference (IV, Fixed, 95% CI) 0.0 [‐0.52, 0.52]
3 Mental Function Impairment MENFIS (change from baseline at 24 weeks) ITT 1 536 Mean Difference (IV, Fixed, 95% CI) ‐0.70 [‐1.72, 0.32]
4 Disability Assessment for Dementia (DAD) (change from baseline at 24 weeks) ITT 1 536 Mean Difference (IV, Fixed, 95% CI) 1.20 [‐0.73, 3.13]
5 CIBIC‐Plus J (no change or worse at 24 weeks) ITT 1 536 Odds Ratio (M‐H, Fixed, 95% CI) 0.67 [0.43, 1.05]
6 BEHAVE‐AD (change from baseline at 24 weeks) ITT 1 536 Mean Difference (IV, Fixed, 95% CI) 0.0 [‐0.67, 0.67]
7 withdrawals before end of treatment at 24 weeks 1 572 Odds Ratio (M‐H, Fixed, 95% CI) 1.53 [1.01, 2.33]
8 at least one adverse event by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 1.80 [1.16, 2.78]
9 withdrawals due to an adverse event before end of treatment at 24 weeks 1 572 Odds Ratio (M‐H, Fixed, 95% CI) 1.96 [1.12, 3.44]
10 at least one adverse event of application site erythema by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 2.53 [1.73, 3.70]
11 at least one adverse event of application site pruritis by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 1.79 [1.23, 2.60]
12 at least one adverse event of application site edema by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 5.65 [2.46, 12.94]
13 at least one adverse event application site exfoliation by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 3.68 [1.20, 11.33]
14 at least one adverse event of dermatitis contact by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 1.99 [1.30, 3.06]
15 at least one adverse event of nasopharyngitis by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 0.67 [0.38, 1.19]
16 at least one adverse event of nausea by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 0.33 [0.09, 1.24]
17 at least one adverse event of vomiting by 24 weeks 1 568 Odds Ratio (M‐H, Fixed, 95% CI) 1.01 [0.43, 2.38]
18 deaths before end of treatment at 24 weeks 1 572 Odds Ratio (M‐H, Fixed, 95% CI) 1.01 [0.06, 16.29]